LOS ANGELES, Oct. 16, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the “Company”) (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/atyr-pharma-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On September 15, 2025, aTyr issued a press release “announce[ing] topline results from the Phase 3 EFZO-FIT(TM) study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease.” The press release disclosed, in relevant part, that the trial had failed to meet its primary endpoint. On this news, aTyr's stock price fell sharply during intraday trading on September 15, 2025. The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq. Attorney Advertising
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
